A series of 31 cases of malignant lymphoplasmacytoid lymphomas (excluding Waldenstrom disease) is analyzed. Two-thirds of the patients initially had localizations elsewhere than in the lymph nodes and presented clinical stage I or II. The median survival is around 4 years and is particularly favorable for stage I and II patients who have received an association of radiotherapy and systematic chemotherapy; the estimated «cure rate » for these patients is around 80 %.
Get full access to this article
View all access options for this article.
References
1.
BerksonJ., GageP.: Survival curve for patients following treatment. J. Amer. Stat. Ass., 47: 501–515, 1952.
2.
BrittingerG., BartelsH., BremerK., BurgerA., DühmkeE., GunzerU., KönigE., StacherA., SteinH., ThemlH., WaldnerR.(Kieler Lymphomgruppe): Retrospektive Untersuchungen zur klinischen Bedeutung der Kiel-Klassifikation der malignant Non-Hodgkin-Lymphome. Strahlentherapie, 153: 222–228, 1977.
3.
CarboneP. P., KaplanH. S., MusshoffK., SmithersD. W., TubianaM.: Report of the committee on Hodgkin's disease staging classification. Cancer Res., 31: 1860–1861, 1971.
4.
ChauvergneJ., HoerniB., DurandM., Hoerni-SimonG., LagardeC.: Chimiothérapie des réticulosarcomes. Résultats d'un essai contrôlé portant sur 60 malades. Nouv. Presse Med., 2: 2039–2041, 1973.
5.
DühmkeE.: Zur klinischen Relevanz der histologischen Differenzierung maligner Non-Hodgkin-Lymphome nach der «Kiel-Klassifikation». Eine retrospektive Studie entsprechender Korrelationen bei 228 Fallen aus Schleswig-Holstein. Strahlentherapie, 152: 129–139, 1976.
6.
DurandM., ChauvergneJ., Hoerni-SimonG., MeugéC., De MascarelA., RichaudP., BrunetR., HoerniB., LagardeC.: Chimiothérapie d'induction des lymphomes malins non hodgkiniens. Résultats d'un essai contrôlé comparant deux quadruples associations. Acta Haemat., 59: 80–87, 1978.
7.
DurandM., HoerniB., ChauvergneJ., RichaudP., Hoerni-SimonG., MeugéC., EghbaliH., LagardeC.: Intérêt d'une chimiothérapie systématique dans le traitement des lymphomes malins au stade clinique I et II. Congrès de Cancérologie de Dakar, mars 1977.
8.
HoerniB., MeugéC., De MascarelA., DurandM., RichaudP., Hoerni-SimonG., Le TreutA., ChauvergneJ., LagardeC.: Les lymphosarcomes immunoblastiques. Aspects anatomo-cliniques et évolutifs. Analyse retrospective d'une série de 50 malades. Nouv. Presse Med., 7: 627–631, 1978.
9.
LagardeC., ChauvergneJ., DurandM., HoerniB., Hoerni-SimonG., TouchardJ.: Intérêt d'une chimiothérapie complémentaire de la radiothérapie dans les stades I et II de la maladie de Hodgkin. Bull. Cancer, 62: 1–10, 1975.
10.
LennertK., MohriN., SteinH., KaiserlingE.: The histopathology of malignant lymphoma. Brit. J. Haemat., 31(suppl. II): 193–203, 1975.
11.
LukesR. J., CollinsR. D.: New approaches to the classification of the lymphomata. Brit. J. Cancer, 31(suppl. II): 1–28, 1975.
12.
MantelN.: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep., 50: 163–170, 1966.
13.
MeugéC., HoerniB., De MascarelA., DurandM., RichaudP., Hoerni-SimonG., ChauvergneJ., LagardeC.: Non-Hodgkin malignant lymphomas. Clinicopathologic correlations with the Kiel classification. Retrospective analysis of a series of 274 cas. Europ. I. Cancer, 1978 (in press).
